Pancrelipase
- Generic Name
- Pancrelipase
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 53608-75-6
- Unique Ingredient Identifier
- FQ3DRG0N5K
- Background
Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010. For further information on the components of this mixture p...
- Indication
The use of pancrelipase amylase is part of the pancreatic enzyme replacement therapy. This therapy is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it. Pancreatic diseases are associated with the deterioration of pancreatic paren...
- Associated Conditions
- Aerophagy, Deficiency Digestive enzymes, Diarrhea, Dyspepsia, Exocrine Pancreatic Insufficiency, Flatulence, Gastrointestinal Discomfort, Pancreatic Insufficiency, Post Operative Gas, Pre-operative Gas, Fat malabsorption, Meteorism
- Associated Therapies
- Bile Duct Disorders, Carbohydrate Digestion, Digestive Aid, Fat Digestion, Liver Metabolism, Protein Digestion
Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT05266963
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT05069597
- Locations
- 🇺🇸
Valley Children's Hospital /ID# 231452, Madera, California, United States
🇺🇸Cleveland Clinic Main Campus /ID# 245864, Cleveland, Ohio, United States
🇺🇸Asr, Llc /Id# 239566, Nampa, Idaho, United States
Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 63
- Registration Number
- NCT04949828
- Locations
- 🇺🇸
John Hopkins University /ID# 227061, Baltimore, Maryland, United States
🇺🇸Baylor College of Medicine - Baylor Medical Center /ID# 227067, Houston, Texas, United States
🇺🇸NYU Langone Health /ID# 230818, New York, New York, United States
Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04315311
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Andrew Hendifar, MD
- Target Recruit Count
- 40
- Registration Number
- NCT04098237
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT03924947
- Locations
- 🇺🇸
Virginia Commonwealth University Medical Center Main Hospital /ID# 164574, Richmond, Virginia, United States
🇺🇸Nationwide Children's Hospital /ID# 225628, Columbus, Ohio, United States
🇺🇸University of Iowa Hospitals and Clinics /ID# 164551, Iowa City, Iowa, United States
A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
- Conditions
- Interventions
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1
- Registration Number
- NCT03859869
- Locations
- 🇺🇸
Fox Chase Cancer Center /ID# 202288, Philadelphia, Pennsylvania, United States
🇺🇸NorthShore University HealthSystem /ID# 209026, Evanston, Illinois, United States
🇺🇸East Carolina University /ID# 206661, Greenville, North Carolina, United States
Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 4
- Registration Number
- NCT03469258
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Massimo Raimondo, M.D.
- Target Recruit Count
- 16
- Registration Number
- NCT02985801
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
CREON for the Treatment of Post-RYGB Hypoglycemia
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- East Carolina University
- Target Recruit Count
- 5
- Registration Number
- NCT02733848
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.